deal

(NASDAQ:MSFT) The pact between Nebius and Microsoft suggests demand for the powerful infrastructure needed to train and run AI models remains strong.

(UPYY) JOHANNESBURG and DALLAS, Sept. 04, 2025 (GLOBE NEWSWIRE) -- UPAY Inc. (OTCQB: UPYY), a U.S.-based fintech innovator, today announced that its South African subsidiary, Automated Credit Provider Administration System (“ACPAS”), has signed a multi-phase development deal with a prominent pan-African financial services group. This group, active across multiple African markets and now entering South Africa, has chosen ACPAS to power the launch of its new digital lending brand.

Expands Presence in Heavy-Truck Sector, Reinforcing Strategic Penetration into High-Risk Commercial Fleets

Applied Digital has finalized a new lease agreement with AI Hyperscaler CoreWeave for an additional 150MW at its Polaris Forge 1 Campus in Ellendale, ND.

STAMFORD, Conn.--(BUSINESS WIRE)--Hildene Capital Management, LLC (“Hildene” or the “Firm”), a $16.8 billion credit-focused alternative asset manager, announced the recent close of CROSS 2025-H6, a $496.3 million securitization. CROSS 2025-H6 is collateralized by a pool of 968 non-qualified residential mortgage (“non-QM”) loans, and has a weighted average FICO score of 748 and a loan-to-value (LTV) ratio of 71.03%. The transaction was rated by Fitch and Kroll, with 96.35% being rated investment

NEW YORK--(BUSINESS WIRE)--Rithm Capital Corp. (NYSE: RITM, “Rithm Capital” or the “Company”), a global, multi-dimensional asset manager with deep experience investing in real estate and credit, today announced the close of NRMLT 2025-NQM4, a $482.6 million securitization backed by a pool of non-qualified residential mortgage (“Non-QM”) loans. The loans are serviced by Rithm’s subsidiary, Newrez LLC, one of the largest mortgage servicers in the US. NRMLT 2025-NQM4 is collateralized by a pool of

– Deal worth up to $885 million based on achievement of certain regulatory and screening guideline milestones – – Final module for the first version of Freenome's colorectal cancer test has been submitted to FDA; approval and commercial launch anticipated in 2026 – – Availability of...